Abstract Library

#3711 Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Homecare is an established delivery method utilised by the UK NHS. In the UK, patients with GEP-NETs on a stable dose of LAN can be trained for self or partner administration or can be administered by a homecare nurse. Both methods remove LAN related activity in an acute setting, negating costs to the provider. The National Tariff payment system is a set of prices to help the NHS deliver value to patients. The price, as set out in the 2022/23 National Tariff workbook, for a single professional follow-up endocrinology outpatient appointment is £101. The cost of this activity, as set out in the 2020/21 National Schedule of Costs, is £197. This represents a potential unreimbursed cost to the NHS of £96 per outpatient appointment.

Conference:

Presenting Author: Bolton R

Authors: Higgs K, Halpin C, Bolton R, Frankcom I,

Keywords: gastroenteropancreatic neuroendocrine tumor, lanreotide autogel, home administration, un-reimbursed costs,

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,

#3455 Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy

Introduction: Intralesional (IL) rose bengal (PV-10) is an investigational autolytic immunotherapy.

Conference:

Presenting Author:

Authors: Price T, Cehic G, Watcher E, Sebbon R, Neuhaus S,

Keywords: PV-10, immunotherapy, phase 1,

#3353 Severe gastroduodenal ulceration following radioactive microspheres treatment in a woman with metastatic neuroendocrine tumor: A case report of paradoxical microsphere migration

Introduction: Incidence of liver metastasis (LM) in advanced NET is high and associated with poor prognosis. SIR-spheres for non-resectable LM in GEP NETs offers symptom regression and survival benefit. Complications are usually local given the SIR-spheres are delivered directly into the hepatic arteries and give off beta emitting radiation. Off target digression of microspheres to other tissues via hepaticoenteric arteries however can result in nearby organ damage.

Conference:

Presenting Author:

Authors: Smith A, Price T, Kitchener M, Trochsler M,

Keywords: SIR-spheres, microspheres, NET,